For Patients with Lennox Gastaut Syndrome (LGS) or Dravet Syndrome

Based on guidance from the FDA, as of April 30, 2015, patients with Lennox Gastaut Syndrome (LGS) or Dravet Syndrome interested in participating in the UAB Open Access CBD Program must first be screened for eligibility in two Randomized Controlled Trials (RCTs) sponsored by GW Pharmaceuticals. The Division of Neurology at the Children's Hospital of Alabama will begin screening patients for participation in these Epidiolex clinical trials in the next few weeks. If you or your child completes the screening process and qualifies for participation in the RCTs sponsored by GW Pharmaceuticals, they can enroll in the Children's of Alabama clinical trial. If you or your child do not meet the eligibility requirements for the clinical trials sponsored by GW Pharmaceuticals and you remain interested in participation in the UAB CBD Program, your 'packet' of medical information, including letter of ineligibility for participation in the RCTs from Children's of Alabama, can be forwarded for review by and qualification to the UAB Open Access Program.

Please see the Randomized Controlled Trial ad posted below and for more information about the study performed by The Division of Neurology at the Children's Hospital of Alabama, contact:

Meredith B. Fitz-Gerald, RN, MSN

Phone: 205-975-2758

For general information about clinical studies or to find a research clinical trial, please visit www.clinicaltrials.gov

GWPCare Studies
Website Design

GWPCare Studies
Website Design